FDA OKs Pfizer's abuse deterrent opioid Troxyca ER
Aug. 20, 2016 3:12 PM ETPfizer Inc. (PFE)By: Douglas W. House, SA News Editor19 Comments
- The FDA approves Pfizer's (NYSE:PFE) abuse-deterrent TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the management of pain severe enough to require around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate.
- The product is formulated in pellets with a core of sequestered naltrexone hydrochloride, an opioid antagonist, surrounded by the pain medication oxycodone hydrochloride. When taken as directed, the naltrexone remains sequestered while the patient receives extended-release oxycodone. When the pellets are crushed, naltrexone is released which counteracts the effects of the opioid.